Liraglutide in a real-world setting: Joint modeling of metabolic response, prediction of efficacy, and cardiovascular risk

The worldwide prevalence of type 2 diabetes mellitus increases in parallel to that of obesity. Liraglutide (LRG), a glucagon-like peptide-1 receptor agonist, can reduce body weight. This study assessed the metabolic efficacy of LRG in real-world clinical practice. An observational, retrospective coh...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Endocrinologia, diabetes y nutricion Ročník 66; číslo 6; s. 376
Hlavní autori:	Alonso-Troncoso, Isabel, Carollo-Limeres, Carmen, Rios-Prego, Mónica, Guler, Ipek, Cadarso-Suárez, Carmen, F-Mariño, Alexis
Médium:	Journal Article
Jazyk:	English Spanish
Vydavateľské údaje:	Spain 01.06.2019
Predmet:	Aged Cardiovascular Diseases - epidemiology Cardiovascular Diseases - etiology Cardiovascular Diseases - prevention & control Cohort Studies Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Female Forecasting Humans Hypoglycemic Agents - therapeutic use Liraglutide - therapeutic use Male Middle Aged Retrospective Studies Risk Factors Treatment Outcome Estudios en vida real Liraglutida Cardiovascular risk Diabetes mellitus tipo 2 Riesgo cardiovascular Real-world studies Efficacy Type 2 diabetes mellitus Liraglutide Eficacia
ISSN:	2530-0180, 2530-0172, 2530-0180
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!